Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Silas Money

Dermatology Lambertville, MI Medical Doctor

NPI 1487221651 CMS profile 9873455

7301 Secor Rd, Lambertville, MI 48144

Open in the dashboard

General payments

$9,255

181 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Silas Money of Lambertville, MI is reported in the CMS Open Payments database as having received $9,255 across 181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,257 41
2024 General $3,159 66
2023 General $2,952 55
2022 General $886 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Silas Money
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Silas Money were reported at $2,257. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Silas Money Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $886 $514 $143–$1,391 $149
2023 $2,952 $607 $159–$1,674 $160
2024 $3,159 $751 $204–$1,903 $164
2025 $2,257 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,037 20 payments
  2. Janssen Biotech, Inc. $1,026 17 payments
  3. Novartis Pharmaceuticals Corporation $982 15 payments
  4. Lilly USA, LLC $697 18 payments
  5. Regeneron Healthcare Solutions, Inc. $670 17 payments
  6. UCB, Inc. $576 8 payments
  7. Amgen Inc. $554 21 payments
  8. Genzyme Corporation $546 11 payments
  9. Janssen Scientific Affairs, LLC $486 5 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $413 6 payments
  11. Other $2,268 43 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $8,643 174 payments
  2. Education $612 7 payments
Products named General payments · program years 2022–2025
  1. TREMFYA $1,512 22 payments
  2. COSENTYX $697 10 payments
  3. SKYRIZI $649 12 payments
  4. Otezla $554 21 payments
  5. DUPIXENT Immunology $533 13 payments
  6. DUPIXENT Inflammation And Immunology $460 11 payments
  7. SPEVIGO $413 6 payments
  8. TALTZ $384 14 payments
  9. Cimzia $333 4 payments
  10. SOTYKTU $316 3 payments
  11. Other $4,170 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

99

Median for Dermatology: 534

Drug cost

$98,692

Median for Dermatology: $67,151

Branded share of claims

14.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 14 $93,995
Tacrolimus Generic 11 $2,628
Fluorouracil Generic 13 $805
Clobetasol Propionate Generic 12 $595
Doxycycline Hyclate Generic 34 $479
Ketoconazole Generic 15 $189

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $266
  • Janssen Scientific Affairs, LLC $208
$474 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $460
$460 — —
SKYRIZI
  • AbbVie, Inc. $340
$340 — —
Bimzelx
  • UCB, Inc. $243
$243 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $230
$230 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record